<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03975257</url>
  </required_header>
  <id_info>
    <org_study_id>btph-021-2018-EHT02</org_study_id>
    <nct_id>NCT03975257</nct_id>
  </id_info>
  <brief_title>Ectoin Lozenges (EHT02) in the Treatment of Oropharyngeal Allergic Symptoms</brief_title>
  <official_title>Application of Ectoin Lozenges (EHT02) in Patients With Oropharyngeal Allergic Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bitop AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bitop AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this multicentric, prospective, randomised, controlled study (§23b German Act on
      Medical Devices (MPG)) is to investigate the efficacy of Ectoin Lozenges (EHT02) in treatment
      and prevention of oropharyngeal allergic symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The immune system of humans can show an overreaction to proteins from the environment
      (allergic reaction). Triggers of these allergic reactions may be e.g. pollen, dust mites,
      mold or animal hair. Common allergic symptoms include itchy, stuffy, runny nose, sneezing,
      itchy and watery eyes and respiratory complaints. Allergen-specific immunotherapy is the only
      treatment that eliminates the causes of allergic disease. An example of such immunotherapies
      is the sublingual immunotherapy (SLIT). During SLIT, side effects may occur such as local
      oropharyngeal reactions, e.g. manifesting as itching, swelling or irritation.

      The current study aims to investigate the efficacy of Ectoin Lozenges (EHT02) in patients
      suffering from oropharyngeal allergic symptoms. The symptoms are induced by SLIT.

      Patients are dedicated to one of three groups: a) preventive application of Ectoin Lozenges
      before SLIT-initiation, b) therapeutic application of Ectoin Lozenges after SLIT-initiation
      or c) control: SLIT-initiation without application of Ectoin Lozenges.

      The symptoms itching, swelling and irritation of mouth, lips and throat will be documented by
      the patients once 30 minutes after SLIT-initiation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 4, 2019</start_date>
  <completion_date type="Actual">September 12, 2019</completion_date>
  <primary_completion_date type="Actual">September 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative score of allergic symptoms of the lips evaluated by the patient</measure>
    <time_frame>about 30 minutes after SLIT-initiation</time_frame>
    <description>about 30 minutes after SLIT-initiation patients will assess allergic symptoms of the lips (swelling, itching and irritation) on a 4 point scale (0=none to 3=severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cumulative score of allergic symptoms of the mouth evaluated by the patient</measure>
    <time_frame>about 30 minutes after SLIT-initiation</time_frame>
    <description>about 30 minutes after SLIT-initiation patients will assess allergic symptoms of the mouth (swelling, itching and irritation) on a 4 point scale (0=none to 3=severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cumulative score of allergic symptoms of the throat evaluated by the patient</measure>
    <time_frame>about 30 minutes after SLIT-initiation</time_frame>
    <description>about 30 minutes after SLIT-initiation patients will assess allergic symptoms of the throat (swelling, itching and irritation) on a 4 point scale (0=none to 3=severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events/serious adverse events</measure>
    <time_frame>through study visit (participation encompasses 1 visit of approx. 60 min duration)</time_frame>
    <description>All occurring adverse events/serious adverse events will be documented during the study.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>Preventive application of EHT02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>application of one Ectoin Lozenge before SLIT-initiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapeutic application of EHT02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>application of one Ectoine Lozenge after SLIT-initiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No application of EHT02</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>SLIT-Initiation without Ectoin Lozenge</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medical Device: Ectoin Lozenge</intervention_name>
    <description>Application of Ectoin Lozenge (EHT02) in accordance with the instructions for use</description>
    <arm_group_label>Preventive application of EHT02</arm_group_label>
    <arm_group_label>Therapeutic application of EHT02</arm_group_label>
    <other_name>EHT02</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  initiation of a SLIT

          -  minimum age of 18 years

          -  written consent of the patient

        Exclusion criteria:

          -  Surgical Procedures in the mouth and throat region prior to the study

          -  patients with known intolerance to one of the substances used

          -  pregnant or breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Bilstein, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>CSO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Facharzt f. HNO-Heilkunde</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachärztin für Hals-Nasen-Ohrenheilkunde</name>
      <address>
        <city>Bad Schönborn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt f. Dermatologie ruhrDerm GbR</name>
      <address>
        <city>Bochum</city>
        <zip>44803</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt für Lungen- und Bronchialheilkunde</name>
      <address>
        <city>Bonn</city>
        <zip>53119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt für Haut und Geschlechtskrankheiten</name>
      <address>
        <city>Gelsenkirchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arzt für Hals-Nasen-Ohrenheilkunde, Allergologie, Umweltmedizin, Naturheilverfahren, Flugmedizin, Taucherarzt (GTÜM)</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachärztin f. HNO-Heilkunde, Allergologie</name>
      <address>
        <city>Jülich</city>
        <zip>52428</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharzt für Hals-Nasen-Ohrenheilkunde, Allergo GmbH Stuttgart, Klinische Prüfstelle Schorndorf</name>
      <address>
        <city>Schorndorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 22, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

